Company profile
Innate Pharma SA
NASDAQ:IPHABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IPH-2101 | phase2 | — | 3 | no active trials |
| LACUTAMAB | phase2 | — | 2 | no active trials |
| Monalizumab | phase1_2 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01256073 | phase1 | completed | 2007-02-01 | 2013-07-01 | Innate Pharma | A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia |
| NCT00552396 | phase1 | completed | 2007-05-01 | 2011-01-01 | Innate Pharma | An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma |
| NCT02557516 | phase1_2 | terminated | 2015-11-09 | 2018-10-29 | Innate Pharma | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL |
| NCT01687387 | phase2 | completed | 2012-10-01 | 2016-11-17 | Innate Pharma | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) |
| NCT02331875 | phase1_2 | terminated | 2014-12-01 | 2016-12-01 | Innate Pharma | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity |
FDA applications (0)
No records yet.